Previous 10 | Next 10 |
Strengthens balance sheet with significant non-dilutive capital Aligned to support FibroGen operational plan Allows for the continued advancement of pamrevlumab, as well as our pre-clinical pipeline FibroGen will receive up to $150 million in total cash ...
2023-04-24 17:17:27 ET Gainers: Medpace Holdings ( MEDP ) +27% . Jupiter Wellness Acquisition ( JWAC ) +4% . Rhythm Pharmaceuticals ( RYTM ) +3% . IDEAYA Biosciences ( IDYA ) +3% . Morphic Holding ( MORF ) +3% . Loser...
SAN FRANCISCO, April 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2023 financial results on Monday, May 8 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further...
- 372 IPF Patients Enrolled - - Topline Data Anticipated Mid-2024 - SAN FRANCISCO, April 03, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the completion of patient enrollment for ZEPHYRUS-2, a Phase 3 clinical study of pamrevlumab in patients with idiopa...
2023-03-29 17:13:07 ET Summary FibroGen is focused on developing pamrevlumab, an innovative drug with potential for IPF treatment, which could capture a share of the multi-billion dollar IPF drug market. The PRAISE study showed pamrevlumab's efficacy and safety in mild-to-moderate...
2023-03-29 14:15:25 ET Summary FibroGen, Inc. got roxa approved in the EU and China, but not in the U.S. The data manipulation problem from two years ago still haunts FibroGen, Inc. That is why, despite some progress with its pipeline, I find it difficult to completely trust F...
Summary Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for fibrosis, inflammation, and related diseases. Its lead drug, bexotegrast, is being developed for Idiopathic Pulmonary Fibrosis (IPF). Bexotegrast is a small molecule ...
FibroGen, Inc. (FGEN) Q4 2022 Earnings Conference Call February 27, 2023, 05:00 PM ET Company Participants Michael Tung - VP of Corporate Strategy and IR Enrique Conterno - CEO Mark Eisner - Chief Medical Officer Juan Graham - CFO Thane Wettig - Chief Commercia...
FibroGen press release ( NASDAQ: FGEN ): Q4 GAAP EPS of -$0.70 beats by $0.25 . Revenue of $34.37M (+107.8% Y/Y) beats by $10.42M . For further details see: FibroGen GAAP EPS of -$0.70 beats by $0.25, revenue of $34.37M beats by $10.42M
Topline Data from Five Pivotal Phase 3 Trials in 2023 Total Company Revenue $140.7 Million in 2022 Continued Strong Roxadustat Volume Growth in China SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...